Christopher D. Anderson

Christopher D. Anderson

Auto-generated profile, based on publicly available information

Christopher D. Anderson

Department of Neurology (C.D.A.), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
RMRainer Malik
Rainer Malik
GCGanesh Chauhan
Ganesh Chauhan
MTMatthew Traylor
Matthew Traylor
MSMuralidharan Sargurupremraj
Muralidharan Sargurupremraj
YOYukinori Okada
Yukinori Okada
MDMartin Dichgans
Martin Dichgans
Stroke has multiple etiologies, but the underlying genes and pathways are largely unknown. We conducted a multiancestry genome-wide-association meta-analysis in 521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 new stroke risk loci, bringing the total to 32. We further found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism, at individual loci (n = 18), and using genetic risk scores and linkage-disequilibrium-score regression. Several loci exhibited distinct association and pleiotropy patterns for etiological stroke subtypes. Eleven new susceptibility loci indicate mechanisms not previously implicated in stroke pathophysiology, with prioritization of risk variants and genes accomplished through bioinformatics analyses using extensive functional datasets. Stroke risk loci were significantly enriched in drug targets for antithrombotic therapy.

11 June 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CRCarolina Roselli
Carolina Roselli
MCMark D. Chaffin
Mark D. Chaffin
LWLu-Chen Weng
Lu-Chen Weng
SAStefanie Aeschbacher
Stefanie Aeschbacher
GAGustav Ahlberg
Gustav Ahlberg
PEPatrick T. Ellinor
Patrick T. Ellinor

21 September 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MUMiriam S. Udler
Miriam S. Udler
JKJaegil Kim
Jaegil Kim
MGMarcin von Grotthuss
Marcin von Grotthuss
SBSílvia Bonàs-Guarch
Sílvia Bonàs-Guarch
JCJoanne B. Cole
Joanne B. Cole
JFJose C. Florez
Jose C. Florez
Type 2 diabetes (T2D) is a heterogeneous disease for which (1) disease-causing pathways are incompletely understood and (2) subclassification may improve patient management. Unlike other biomarkers, germline genetic markers do not change with disease progression or treatment. In this paper, we test whether a germline genetic approach informed by physiology can be used to deconstruct T2D heterogeneity. First, we aimed to categorize genetic loci into groups representing likely disease mechanistic pathways. Second, we asked whether the novel clusters of genetic loci we identified have any broad clinical consequence, as assessed in four separate subsets of individuals with T2D. In an effort to identify mechanistic pathways driven by established T2D genetic loci, we applied Bayesian nonnegative matrix factorization (bNMF) clustering to genome-wide association study (GWAS) results for 94 independent T2D genetic variants and 47 diabetes-related traits. We identified five robust clusters of T2D loci and traits, each with distinct tissue-specific enhancer enrichment based on analysis of epigenomic data from 28 cell types. Two clusters contained variant-trait associations indicative of reduced beta cell function, differing from each other by high versus low proinsulin levels. The three other clusters displayed features of insulin resistance: obesity mediated (high body mass index [BMI] and waist circumference [WC]), “lipodystrophy-like” fat distribution (low BMI, adiponectin, and high-density lipoprotein [HDL] cholesterol, and high triglycerides), and disrupted liver lipid metabolism (low triglycerides). Increased cluster genetic risk scores were associated with distinct clinical outcomes, including increased blood pressure, coronary artery disease (CAD), and stroke. We evaluated the potential for clinical impact of these clusters in four studies containing individuals with T2D (Metabolic Syndrome in Men Study [METSIM], N = 487; Ashkenazi, N = 509; Partners Biobank, N = 2,065; UK Biobank [UKBB], N = 14,813). Individuals with T2D in the top genetic risk score decile for each cluster reproducibly exhibited the predicted cluster-associated phenotypes, with approximately 30% of all individuals assigned to just one cluster top decile. Limitations of this study include that the genetic variants used in the cluster analysis were restricted to those associated with T2D in populations of European ancestry. Our approach identifies salient T2D genetically anchored and physiologically informed pathways, and supports the use of genetics to deconstruct T2D heterogeneity. Classification of patients by these genetic pathways may offer a step toward genetically informed T2D patient management.

17 April 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
ICIngrid E Christophersen
Ingrid E Christophersen
MRMichiel Rienstra
Michiel Rienstra
CRCarolina Roselli
Carolina Roselli
XYXiaoyan Yin
Xiaoyan Yin
BGBastiaan Geelhoed
Bastiaan Geelhoed
TCthe AFGen Consortium
the AFGen Consortium

8 November 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
SKShaan Khurshid
Shaan Khurshid
SFSamuel Friedman
Samuel Friedman
CRChristopher Reeder
Christopher Reeder
PAPaolo Di Achille
Paolo Di Achille
NDNathaniel Diamant
Nathaniel Diamant
SLSteven A. Lubitz
Steven A. Lubitz
Background: Artificial intelligence (AI)–enabled analysis of 12-lead ECGs may facilitate efficient estimation of incident atrial fibrillation (AF) risk. However, it remains unclear whether AI provides meaningful and generalizable improvement in predictive accuracy beyond clinical risk factors for AF. Methods: We trained a convolutional neural network (ECG-AI) to infer 5-year incident AF risk using 12-lead ECGs in patients receiving longitudinal primary care at Massachusetts General Hospital (MGH). We then fit 3 Cox proportional hazards models, composed of ECG-AI 5-year AF probability, CHARGE-AF clinical risk score (Cohorts for Heart and Aging in Genomic Epidemiology–Atrial Fibrillation), and terms for both ECG-AI and CHARGE-AF (CH-AI), respectively. We assessed model performance by calculating discrimination (area under the receiver operating characteristic curve) and calibration in an internal test set and 2 external test sets (Brigham and Women’s Hospital [BWH] and UK Biobank). Models were recalibrated to estimate 2-year AF risk in the UK Biobank given limited available follow-up. We used saliency mapping to identify ECG features most influential on ECG-AI risk predictions and assessed correlation between ECG-AI and CHARGE-AF linear predictors. Results: The training set comprised 45 770 individuals (age 55±17 years, 53% women, 2171 AF events) and the test sets comprised 83 162 individuals (age 59±13 years, 56% women, 2424 AF events). Area under the receiver operating characteristic curve was comparable using CHARGE-AF (MGH, 0.802 [95% CI, 0.767–0.836]; BWH, 0.752 [95% CI, 0.741–0.763]; UK Biobank, 0.732 [95% CI, 0.704–0.759]) and ECG-AI (MGH, 0.823 [95% CI, 0.790–0.856]; BWH, 0.747 [95% CI, 0.736–0.759]; UK Biobank, 0.705 [95% CI, 0.673–0.737]). Area under the receiver operating characteristic curve was highest using CH-AI (MGH, 0.838 [95% CI, 0.807 to 0.869]; BWH, 0.777 [95% CI, 0.766 to 0.788]; UK Biobank, 0.746 [95% CI, 0.716 to 0.776]). Calibration error was low using ECG-AI (MGH, 0.0212; BWH, 0.0129; UK Biobank, 0.0035) and CH-AI (MGH, 0.012; BWH, 0.0108; UK Biobank, 0.0001). In saliency analyses, the ECG P-wave had the greatest influence on AI model predictions. ECG-AI and CHARGE-AF linear predictors were correlated (Pearson r : MGH, 0.61; BWH, 0.66; UK Biobank, 0.41). Conclusions: AI-based analysis of 12-lead ECGs has similar predictive usefulness to a clinical risk factor model for incident AF and the approaches are complementary. ECG-AI may enable efficient quantification of future AF risk.

1 April 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
DWDaniel Woo
Daniel Woo
GFGuido J. Falcone
Guido J. Falcone
WDWilliam J. Devan
William J. Devan
WBW. Mark Brown
W. Mark Brown
ABAlessandro Biffi
Alessandro Biffi
JRJonathan Rosand
Jonathan Rosand